A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations
Clinical and Translational Science · 2023
DOI: 10.1111/cts.13527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Claire Steinbronn und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Hydroxychloroquine, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Hydroxychloroquine (HCQ) is Food and Drug Administration (FDA)‐approved for malaria, systemic and chronic discoid lupus erythematosus, and rheumatoid arthritis. Because HCQ has a proposed multimodal mechanism of action and a well‐established safety profile, it is often investigated as a repurposed therapeutic for a range of indications. There is a large degree of uncertainty in HCQ pharmacokinetic (PK) parameters which complicates dose selection when investigating its use in new disease states. Complications with HCQ dose selection emerged as multiple clinical trials investigated HCQ as a potential therapeutic in the early stages of the COVID‐19 pandemic. In addition to uncertainty in baseline HCQ PK parameters, it was not clear if disease‐related consequences of SARS‐CoV‐2 infection/COVID‐19 would be expected to impact the PK of HCQ and its primary metabolite desethylhydroxychloroquine (DHCQ). To address the question whether SARS‐CoV‐2 infection/COVID‐19 impacted HCQ and DHCQ PK, dried blood spot samples were collected from SARS‐CoV‐2(−)/(+) participants administered HCQ. When a previously published physiologically based pharmacokinetic (PBPK) model was used to fit the data, the variability in exposure of HCQ and DHCQ was not adequately captured and DHCQ concentrations were overestimated. Improvements to the previous PBPK model were made by incorporating the known range of blood to plasma concentration ratios (B/P) for each compound, adjusting HCQ and DHCQ distribution settings, and optimizing DHCQ clearance. The final PBPK model adequately captured the HCQ and DHCQ concentrations observed in SARS‐CoV‐2(−)/(+)participants, and incorporating COVID‐19‐associated changes in cytochrome P450 activity did not further improve model performance for the SARS‐CoV‐2(+) population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
- Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Division of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Medicine, University of Washington, Seattle, Washington, USA.
- Department of Global Health, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Jenell Stewart, Mark Wener, Daryl J Murry, Samuel L M Arnold
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Steinbronn, C., Chhonker, Y. S., Stewart, J., Leingang, H., Heller, K. B., Krows, M. L., Paasche-Orlow, M., Bershteyn, A., Stankiewicz Karita, H. C., Agrawal, V., Laufer, M., Landovitz, R., Wener, M., Murry, D. J., Johnston, C., Barnabas, R. V., & Arnold, S. L. M. (2023). A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations. Clinical and Translational Science. https://doi.org/10.1111/cts.13527
Vancouver
Steinbronn C, Chhonker YS, Stewart J, Leingang H, Heller KB, Krows ML, et al. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations. Clinical and Translational Science. 2023. doi:10.1111/cts.13527
BibTeX
@article{Steinbronn2023,
author = {Steinbronn, Claire and Chhonker, Yashpal S and Stewart, Jenell and Leingang, Hannah and Heller, Kate B and Krows, Meighan L and Paasche-Orlow, Michael and Bershteyn, Anna and Stankiewicz Karita, Helen C and Agrawal, Vaidehi and Laufer, Miriam and Landovitz, Raphael and Wener, Mark and Murry, Daryl J and Johnston, Christine and Barnabas, Ruanne V and Arnold, Samuel L M},
title = {A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations},
journal = {Clinical and Translational Science},
year = {2023},
doi = {10.1111/cts.13527}
}
EUVIMED